Heart valve treatment is moving toward procedures that can address serious cardiac conditions without requiring traditional open-heart surgery. Transcatheter heart valve (THV) technologies are becoming increasingly important for patients with conditions such as aortic stenosis, mitral regurgitation, and other structural heart diseases. As populations age and minimally invasive treatment options advance, the transcatheter heart valve market is entering a period of substantial expansion.

The global Transcatheter Heart Valve Market was valued at USD 5.5 billion in 2024 and is projected to reach USD 21.2 billion by 2033, increasing from USD 7.2 billion in 2026. The market is expected to grow at a CAGR of 16.5% from 2025 to 2033. North America accounted for 48.3% of revenue in 2024, while Asia Pacific is projected to be the fastest-growing regional market.

The Clinical Need Behind Market Expansion

Heart valve diseases can interfere with the normal flow of blood through the heart and may lead to serious complications when left untreated. Aortic stenosis and mitral regurgitation are important conditions driving demand for transcatheter interventions, particularly among older adults.

According to the supplied source, the U.S. Centers for Disease Control and Prevention reported in September 2024 that 75% of U.S. adults had limited knowledge of heart valve disease. More than 5 million people in the country receive a diagnosis of heart valve disease each year, while annual fatalities attributed to the condition exceed 25,000.

These figures highlight the importance of disease awareness alongside treatment innovation. As diagnosis and access to advanced cardiac care improve, more patients may be evaluated for transcatheter procedures.

Aortic Valve Procedures Remain the Market's Core

Transcatheter aortic valve applications accounted for 81.67% of market revenue in 2024. Their leading position reflects the prevalence of aortic valve disease, particularly severe aortic stenosis, and the increasing availability of minimally invasive replacement technologies.

Transcatheter aortic valve replacement (TAVR), also known as transcatheter aortic valve implantation (TAVI), enables physicians to replace a diseased valve using a catheter-based approach. Compared with traditional open-heart surgery, these procedures can offer shorter recovery periods and reduced procedural burden for appropriately selected patients.

The transcatheter mitral valve segment is expected to record the fastest CAGR during the forecast period. Demand for less invasive treatment of mitral valve disease is encouraging companies to advance replacement technologies and address unmet needs in structural heart care.

Download a free sample report or claim your copy of this full market intelligence report

Valve Engineering Is Becoming a Competitive Differentiator

The development of transcatheter heart valves involves more than improving the valve itself. Manufacturers are working on delivery mechanisms, positioning accuracy, durability, and materials that can help reduce complications and support better patient outcomes.

Self-expanding valves held the largest technology share in 2024, accounting for 63.97%. Their established presence and broad clinical use support this position. Balloon-expandable valves, however, are projected to experience the highest CAGR during the forecast period as technology advances and clinical adoption expands.

Imaging improvements, including three-dimensional computed tomography and real-time procedural guidance, are also influencing treatment planning. AI-driven simulation and more refined delivery systems may further support device placement and procedural precision.

Product developments illustrate this innovation cycle. In August 2024, Boston Scientific announced CE Mark approval for its ACURATE Prime Aortic Valve System, which includes a new valve size intended for patients with larger anatomies. In April 2024, Abbott received U.S. FDA approval for its TriClip system, a transcatheter edge-to-edge repair technology for tricuspid regurgitation.

New Materials and Broader Treatment Options

Valve durability is a central consideration in product development. Edwards Lifesciences' SAPIEN 3 Ultra RESILIA valve uses RESILIA bovine-pericardial leaflet tissue designed to resist calcification and support dry storage. These material characteristics address important considerations in device handling and long-term performance.

Companies are also expanding their product portfolios to cover a wider range of valve anatomies and patient needs. In September 2025, Edwards Lifesciences launched its next-generation balloon-expandable transcatheter heart valve platform in India, according to the supplied source. The platform incorporates calcification-resistant tissue technology intended to improve long-term valve performance.

In another development, Foldax announced in April 2024 that its TRIA heart valves had exceeded 200 patient life-years in human recipients. The valves use the company's proprietary LifePolymer material, designed to improve durability and minimize calcification.

Key Companies and Strategic Moves

The competitive landscape includes established cardiovascular device manufacturers and companies developing specialized transcatheter technologies.

• Edwards Lifesciences Corporation: Expanding its structural heart portfolio and advancing valve materials, delivery systems, and transcatheter mitral and tricuspid therapies.
• Abbott: Developing a broad range of transcatheter technologies, including the Portico and Navitor aortic valve systems and the TriClip repair system.
• Medtronic: Extending its cardiac valve portfolio, including the launch of the Avalus Ultra surgical aortic valve in India in October 2025.
• Boston Scientific: Advancing its transcatheter aortic valve offerings through the ACURATE Prime system.
• Meril Life Sciences: Participating in the development and expansion of transcatheter valve technologies, including its Myval platform.

Mergers and acquisitions are also influencing competition. Edwards Lifesciences acquired JC Medical in August 2024, gaining its J-Valve technology for severe symptomatic native aortic regurgitation. In July 2024, the company announced its acquisition of Innovalve Bio Medical to strengthen its transcatheter mitral valve replacement capabilities.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Regional Adoption: Established Markets and New Demand

North America held the largest regional share in 2024, supported by advanced healthcare infrastructure, strong healthcare spending, and established adoption of minimally invasive cardiac procedures. The United States remains a major market because of its clinical research activity, regulatory framework, and presence of leading device manufacturers.

Europe is expected to experience significant growth, with Germany, France, and the United Kingdom contributing to adoption. In August 2025, Abbott received CE Mark approval for an expanded indication of its Navitor TAVI system for selected low- and intermediate-risk patients with severe symptomatic aortic stenosis.

Asia Pacific is projected to grow at the fastest rate as cardiovascular disease prevalence, aging populations, and healthcare investment increase demand for advanced interventions. China and Japan are important markets, while India is seeing growing activity in cardiac technology development and access to minimally invasive treatment.

Opportunities are also emerging in Latin America and the Middle East and Africa. Brazil's approval of MicroPort CardioFlow's VitaFlow Liberty TAVI system in May 2025 and Cleveland Clinic Abu Dhabi's completion of 500 TAVI procedures in October 2024 illustrate the expansion of these technologies beyond the most established markets.

The Next Stage of Transcatheter Cardiac Care

With the market projected to reach USD 21.2 billion by 2033, future growth will depend on continued improvements in valve design, clinical evidence, and access to minimally invasive procedures. Aortic valve replacement currently anchors demand, while mitral and tricuspid interventions offer additional avenues for development.

For device manufacturers, the opportunity lies in creating durable, precisely deployable technologies that address a wider range of patients. For healthcare systems, earlier diagnosis and broader access to experienced cardiac teams will be important to translating technological progress into better patient outcomes.

Explore Our Research & Intelligence Solutions

Prism AI: Ask. Analyze. Get Cited Market Insights. – Explore Now

U.S. Healthcare Facility Intelligence: Make Better Decisions with Comprehensive Data – Explore the Platform